Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Income from Continuing Operations (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Income from Continuing Operations readings, the most recent being 16988000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 65.98% to 16988000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 24167000.0 through Mar 2026, up 3.23% year-over-year, with the annual reading at 17414000.0 for FY2025, 34.12% up from the prior year.
  • Income from Continuing Operations hit 16988000.0 in Q1 2026 for Ovid Therapeutics, down from 9663000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 9663000.0 in Q4 2025 and bottomed at 16988000.0 in Q1 2026.
  • Average Income from Continuing Operations over 5 years is 9843648.82, with a median of 11967771.0 recorded in 2022.
  • Peak annual rise in Income from Continuing Operations hit 204.43% in 2025, while the deepest fall reached 154.97% in 2025.
  • Ovid Therapeutics' Income from Continuing Operations stood at 11504789.0 in 2022, then plummeted by 33.18% to 15322000.0 in 2023, then skyrocketed by 39.61% to 9253000.0 in 2024, then skyrocketed by 204.43% to 9663000.0 in 2025, then crashed by 275.8% to 16988000.0 in 2026.
  • Per Business Quant, the three most recent readings for OVID's Income from Continuing Operations are 16988000.0 (Q1 2026), 9663000.0 (Q4 2025), and 12158000.0 (Q3 2025).